Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.59 |
| ▸ | ADH1A | P07327 | 4/20 | 0.59 |
| ▸ | ADH1C | P00326 | 3/20 | 0.54 |
| ▸ | ADH7 | P40394 | 2/20 | 0.54 |
| ▸ | ADH4 | P08319 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14231203 | 0.92 | ADH1B (0.58) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL23173285 | 0.87 | ADH1B (0.56) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL771083 | 0.86 | — | — | |
| SCHEMBL799528 | 0.86 | — | — | |
| SCHEMBL359530 | 0.86 | — | — | |
| SCHEMBL4771257 | 0.80 | ADH1B (0.52) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL7516381 | 0.78 | ADH1B (0.62) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL27660973 | 0.77 | KDM4E (0.36) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL21422780 | 0.76 | KDM1A (0.47) | POLBKAT2BNCF1KDM1ADPP7 | |
| SCHEMBL22866378 | 0.76 | ADH1B (0.59) | ADH1BADH1AADH1CADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641886-A | bicyclic BET bromodomain inhibitors and uses thereof | 康威基内有限公司 | 2019-04-16 | — | — | CN | claimed |
| CN-106243100-B | Treat alcohol use disorders, the pharmaceutical composition and method of pain and other diseases | VM生物医药公司 | 2019-04-09 | — | — | CN | claimed |
| CN-108699106-A | Novel trifluoromethyl propanamide derivative as HTRA1 inhibitor | 豪夫迈·罗氏有限公司 | 2018-10-23 | — | — | CN | claimed |
| EP-1268426-B1 | 4-FORMYL AMINO-N-METHYLPIPERIDINE DERIVATIVES, THE USE THEREOF AS STABILISERS AND ORGANIC MATERIAL STABILISED THEREWITH | BASF SE (DE) | 2013-09-18 | — | — | EP | claimed |
| EP-1713806-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-05-08 | — | — | EP | claimed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | claimed |
| US-7968557-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | NOVARTIS AG (CH) | 2011-06-28 | — | — | US | claimed |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | claimed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | claimed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | claimed |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2007-09-27 | — | — | US | claimed |
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | PALUMED S.A. (FR) | 2007-03-15 | — | — | US | claimed |
| EP-1713806-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | claimed |
| WO-2005107760-A1 | COMPOUNDS AND COMPOSITIONS AS INDUCERS OF KERATINOCYTE DIFFERENTIATION | IRM LLC (BM) | 2005-11-17 | — | — | WO | claimed |
| WO-2005080393-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-09-01 | — | — | WO | claimed |
| US-6737527-B2 | IN PARTICULAR FOR STABILIZING PLASTICS OR COATING MATERIALS; PHOTOSTABILITY | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-18 | — | — | US | claimed |
| US-20030083406-A1 | 4-Formyl amino-n-methylpiperidine derivatives, the use thereof as stabilisers and organic material stabilised therewith | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-01 | — | — | US | claimed |
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | claimed |
| EP-0149840-B1 | Substituted 5,11-dihydro-6H-dibenz[b,e]azepin-6-ones, method for their preparation and these compounds containing medicines | Dr. Karl Thomae GmbH (DE) | 1989-04-26 | — | — | EP | claimed |
| US-4567178-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1986-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | ADH1B 4400/4885ADH1A 3780/4885ADH1C 3268/4885 |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | ADH1B 2172/4885ADH1A 2338/4885ADH1C 2467/4885 |
| US-20030083406-A1 | 4-Formyl amino-n-methylpiperidine derivatives, the use thereof as stabilisers and organic material stabilised therewith | PNMT, INMT, AZI2 | ADH1B 1385/4885ADH1A 552/4885ADH1C 692/4885 |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ABL1, PDGFRA, PDGFRB | ADH1B 4876/4885ADH1A 4869/4885ADH1C 4650/4885 |
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | QARS1, QPCT, QTRT2 | ADH1B 4095/4885ADH1A 4103/4885ADH1C 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.